Nplex was formed in 2012 and has an exclusive license to the membrane technology and has been developing the core technology with The Burnet Institute, Deakin University and Planet Innovation. The platform is unique due its ability to quantitate at low limits of detection, with very low sample volumes and in a rapid format. The patented membrane in combination with a fluorescent sensing system enables multiplexing up to five tests at once, which broadens the screening and monitoring applications.
The novel technology addresses the fundamental limitations of nitrocellulose based lateral flow tests, overcoming the poor sensitivity and high variation in test result in that format. For screening tests, we will offer unparalleled levels of sensitivity, not available from other commercially available lateral flow reader technologies, and for quantitated tests, enable the cost effective transition of these tests further out towards the patient.